Ophthalmic Drugs Market (Disease Indication: Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, and Others; and Product Type: Prescription Drugs and OTC Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Ophthalmic Drugs Market – Scope of Report
TMR’s report on the global ophthalmic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ophthalmic drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ophthalmic drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ophthalmic drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ophthalmic drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ophthalmic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ophthalmic drugs market.
The report delves into the competitive landscape of the global ophthalmic drugs market. Key players operating in the global ophthalmic drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ophthalmic drugs market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ophthalmic drugs.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Ophthalmic Drugs Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Disease Indication Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Ophthalmic Drugs Market Analysis and Forecast, 2017–2031
- 5. Key Insights
- 5.1. Technological Advancements
- 5.2. Pipeline Analysis
- 5.3. Disease Prevalence & Incidence Rate globally with key countries
- 5.4. Key Mergers & Acquisitions
- 5.5. COVID-19 Impact
- 6. Global Ophthalmic Drugs Market Analysis and Forecast, By Disease Indication
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast By Disease Indication, 2017–2031
- 6.3.1. Dry Eye
- 6.3.2. Glaucoma
- 6.3.3. Infection/Inflammation
- 6.3.4. Retinal Disorders
- 6.3.4.1. Wet AMD
- 6.3.4.2. Dry AMD
- 6.3.4.3. Diabetic Retinopathy
- 6.3.4.4. Others
- 6.3.5. Allergy
- 6.3.6. Uveitis
- 6.3.7. Others
- 6.4. Market Attractiveness By Disease Indication
- 7. Global Ophthalmic Drugs Market Analysis and Forecast, By Therapeutic Class
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 7.3.1. Anti-inflammatory Drugs
- 7.3.1.1. NSAIDs
- 7.3.1.2. Steroids
- 7.3.2. Anti-infective Drugs
- 7.3.2.1. Anti-fungal Drugs
- 7.3.2.2. Anti-bacterial Drugs
- 7.3.2.3. Others
- 7.3.3. Anti-glaucoma Drugs
- 7.3.3.1. Alpha Agonist
- 7.3.3.2. Beta Blockers
- 7.3.3.3. Prostaglandin Analogs
- 7.3.3.4. Combined Medication
- 7.3.3.5. Others
- 7.3.4. Anti-allergy Drugs
- 7.3.5. Anti-VEGF Agents
- 7.3.6. Others
- 7.4. Market Attractiveness By Therapeutic Class
- 8. Global Ophthalmic Drugs Market Analysis and Forecast, By Product Type
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast By Product Type, 2017–2031
- 8.3.1. Prescription Drugs
- 8.3.2. OTC Drugs
- 8.4. Market Attractiveness By Product Type
- 9. Global Ophthalmic Drugs Market Analysis and Forecast, By Distribution Channel
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast By Distribution Channel, 2017–2031
- 9.3.1. Hospital Pharmacies
- 9.3.2. Online Pharmacies
- 9.3.3. Independent Pharmacies & Drug Stores
- 9.4. Market Attractiveness By Distribution Channel
- 10. Global Ophthalmic Drugs Market Analysis and Forecast, By Region
- 10.1. Key Findings
- 10.2. Market Value Forecast By Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness By Country/Region
- 11. North America Ophthalmic Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast By Disease Indication, 2017–2031
- 11.2.1. Dry Eye
- 11.2.2. Glaucoma
- 11.2.3. Infection/Inflammation
- 11.2.4. Retinal Disorders
- 11.2.4.1. Wet AMD
- 11.2.4.2. Dry AMD
- 11.2.4.3. Diabetic Retinopathy
- 11.2.4.4. Others
- 11.2.5. Allergy
- 11.2.6. Uveitis
- 11.2.7. Others
- 11.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 11.3.1. Anti-inflammatory Drugs
- 11.3.1.1. NSAIDs
- 11.3.1.2. Steroids
- 11.3.2. Anti-infective Drugs
- 11.3.2.1. Anti-fungal Drugs
- 11.3.2.2. Anti-bacterial Drugs
- 11.3.2.3. Others
- 11.3.3. Anti-glaucoma Drugs
- 11.3.3.1. Alpha Agonist
- 11.3.3.2. Beta Blockers
- 11.3.3.3. Prostaglandin Analogs
- 11.3.3.4. Combined Medication
- 11.3.3.5. Others
- 11.3.4. Anti-allergy Drugs
- 11.3.5. Anti-VEGF Agents
- 11.3.6. Others
- 11.4. Market Value Forecast By Product Type, 2017–2031
- 11.4.1. Prescription Drugs
- 11.4.2. OTC Drugs
- 11.5. Market Value Forecast By Distribution Channel, 2017–2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Online Pharmacies
- 11.5.3. Independent Pharmacies & Drug Stores
- 11.6. Market Value Forecast By Country, 2017–2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Disease Indication
- 11.7.2. By Therapeutic Class
- 11.7.3. By Product Type
- 11.7.4. By Distribution Channel
- 11.7.5. By Country
- 12. Europe Ophthalmic Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast By Disease Indication, 2017–2031
- 12.2.1. Dry Eye
- 12.2.2. Glaucoma
- 12.2.3. Infection/Inflammation
- 12.2.4. Retinal Disorders
- 12.2.4.1. Wet AMD
- 12.2.4.2. Dry AMD
- 12.2.4.3. Diabetic Retinopathy
- 12.2.4.4. Others
- 12.2.5. Allergy
- 12.2.6. Uveitis
- 12.2.7. Others
- 12.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 12.3.1. Anti-inflammatory Drugs
- 12.3.1.1. NSAIDs
- 12.3.1.2. Steroids
- 12.3.2. Anti-infective Drugs
- 12.3.2.1. Anti-fungal Drugs
- 12.3.2.2. Anti-bacterial Drugs
- 12.3.2.3. Others
- 12.3.3. Anti-glaucoma Drugs
- 12.3.3.1. Alpha Agonist
- 12.3.3.2. Beta Blockers
- 12.3.3.3. Prostaglandin Analogs
- 12.3.3.4. Combined Medication
- 12.3.3.5. Others
- 12.3.4. Anti-allergy Drugs
- 12.3.5. Anti-VEGF Agents
- 12.3.6. Others
- 12.4. Market Value Forecast By Product Type, 2017–2031
- 12.4.1. Prescription Drugs
- 12.4.2. OTC Drugs
- 12.5. Market Value Forecast By Distribution Channel, 2017–2031
- 12.5.1. Hospital Pharmacies
- 12.5.2. Online Pharmacies
- 12.5.3. Independent Pharmacies & Drug Stores
- 12.6. Market Value Forecast By Country, 2017–2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Disease Indication
- 12.7.2. By Therapeutic Class
- 12.7.3. By Product Type
- 12.7.4. By Distribution Channel
- 12.7.5. By Country
- 13. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast By Disease Indication, 2017–2031
- 13.2.1. Dry Eye
- 13.2.2. Glaucoma
- 13.2.3. Infection/Inflammation
- 13.2.4. Retinal Disorders
- 13.2.4.1. Wet AMD
- 13.2.4.2. Dry AMD
- 13.2.4.3. Diabetic Retinopathy
- 13.2.4.4. Others
- 13.2.5. Allergy
- 13.2.6. Uveitis
- 13.2.7. Others
- 13.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 13.3.1. Anti-inflammatory Drugs
- 13.3.1.1. NSAIDs
- 13.3.1.2. Steroids
- 13.3.2. Anti-infective Drugs
- 13.3.2.1. Anti-fungal Drugs
- 13.3.2.2. Anti-bacterial Drugs
- 13.3.2.3. Others
- 13.3.3. Anti-glaucoma Drugs
- 13.3.3.1. Alpha Agonist
- 13.3.3.2. Beta Blockers
- 13.3.3.3. Prostaglandin Analogs
- 13.3.3.4. Combined Medication
- 13.3.3.5. Others
- 13.3.4. Anti-allergy Drugs
- 13.3.5. Anti-VEGF Agents
- 13.3.6. Others
- 13.4. Market Value Forecast By Product Type, 2017–2031
- 13.4.1. Prescription Drugs
- 13.4.2. OTC Drugs
- 13.5. Market Value Forecast By Distribution Channel, 2017–2031
- 13.5.1. Hospital Pharmacies
- 13.5.2. Online Pharmacies
- 13.5.3. Independent Pharmacies & Drug Stores
- 13.6. Market Value Forecast By Country, 2017–2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Disease Indication
- 13.7.2. By Therapeutic Class
- 13.7.3. By Product Type
- 13.7.4. By Distribution Channel
- 13.7.5. By Country
- 14. Latin America Ophthalmic Drugs Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast By Disease Indication, 2017–2031
- 14.2.1. Dry Eye
- 14.2.2. Glaucoma
- 14.2.3. Infection/Inflammation
- 14.2.4. Retinal Disorders
- 14.2.4.1. Wet AMD
- 14.2.4.2. Dry AMD
- 14.2.4.3. Diabetic Retinopathy
- 14.2.4.4. Others
- 14.2.5. Allergy
- 14.2.6. Uveitis
- 14.2.7. Others
- 14.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 14.3.1. Anti-inflammatory Drugs
- 14.3.1.1. NSAIDs
- 14.3.1.2. Steroids
- 14.3.2. Anti-infective Drugs
- 14.3.2.1. Anti-fungal Drugs
- 14.3.2.2. Anti-bacterial Drugs
- 14.3.2.3. Others
- 14.3.3. Anti-glaucoma Drugs
- 14.3.3.1. Alpha Agonist
- 14.3.3.2. Beta Blockers
- 14.3.3.3. Prostaglandin Analogs
- 14.3.3.4. Combined Medication
- 14.3.3.5. Others
- 14.3.4. Anti-allergy Drugs
- 14.3.5. Anti-VEGF Agents
- 14.3.6. Others
- 14.4. Market Value Forecast By Product Type, 2017–2031
- 14.4.1. Prescription Drugs
- 14.4.2. OTC Drugs
- 14.5. Market Value Forecast By Distribution Channel, 2017–2031
- 14.5.1. Hospital Pharmacies
- 14.5.2. Online Pharmacies
- 14.5.3. Independent Pharmacies & Drug Stores
- 14.6. Market Value Forecast By Country, 2017–2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Disease Indication
- 14.7.2. By Therapeutic Class
- 14.7.3. By Product Type
- 14.7.4. By Distribution Channel
- 14.7.5. By Country
- 15. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast By Disease Indication, 2017–2031
- 15.2.1. Dry Eye
- 15.2.2. Glaucoma
- 15.2.3. Infection/Inflammation
- 15.2.4. Retinal Disorders
- 15.2.4.1. Wet AMD
- 15.2.4.2. Dry AMD
- 15.2.4.3. Diabetic Retinopathy
- 15.2.4.4. Others
- 15.2.5. Allergy
- 15.2.6. Uveitis
- 15.2.7. Others
- 15.3. Market Value Forecast By Therapeutic Class, 2017–2031
- 15.3.1. Anti-inflammatory Drugs
- 15.3.1.1. NSAIDs
- 15.3.1.2. Steroids
- 15.3.2. Anti-infective Drugs
- 15.3.2.1. Anti-fungal Drugs
- 15.3.2.2. Anti-bacterial Drugs
- 15.3.2.3. Others
- 15.3.3. Anti-glaucoma Drugs
- 15.3.3.1. Alpha Agonist
- 15.3.3.2. Beta Blockers
- 15.3.3.3. Prostaglandin Analogs
- 15.3.3.4. Combined Medication
- 15.3.3.5. Others
- 15.3.4. Anti-allergy Drugs
- 15.3.5. Anti-VEGF Agents
- 15.3.6. Others
- 15.4. Market Value Forecast By Product Type, 2017–2031
- 15.4.1. Prescription Drugs
- 15.4.2. OTC Drugs
- 15.5. Market Value Forecast By Distribution Channel, 2017–2031
- 15.5.1. Hospital Pharmacies
- 15.5.2. Online Pharmacies
- 15.5.3. Independent Pharmacies & Drug Stores
- 15.6. Market Value Forecast By Country, 2017–2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
- 15.7.1. By Disease Indication
- 15.7.2. By Therapeutic Class
- 15.7.3. By Product Type
- 15.7.4. By Distribution Channel
- 15.7.5. By Country
- 16. Competition Landscape
- 16.1. Market Player - Competition Matrix (by tier and size of companies)
- 16.2. Market Share Analysis, by Company, 2021
- 16.3. Company Profiles
- 16.3.1. Aerie Pharmaceuticals, Inc.
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. SWOT Analysis
- 16.3.1.4. Strategic Overview
- 16.3.2. Allergan plc
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. SWOT Analysis
- 16.3.2.4. Strategic Overview
- 16.3.3. Valeant Pharmaceuticals International, Inc.
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. SWOT Analysis
- 16.3.3.4. Strategic Overview
- 16.3.4. Bayer AG
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. SWOT Analysis
- 16.3.4.4. Strategic Overview
- 16.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. SWOT Analysis
- 16.3.5.4. Strategic Overview
- 16.3.6. Novartis AG.
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. SWOT Analysis
- 16.3.6.4. Strategic Overview
- 16.3.7. Pfizer Inc.
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. SWOT Analysis
- 16.3.7.4. Strategic Overview
- 16.3.8. Regeneron Pharmaceuticals, Inc
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. SWOT Analysis
- 16.3.8.4. Strategic Overview
- 16.3.9. Santen Pharmaceutical Co., Ltd
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Product Portfolio
- 16.3.9.3. SWOT Analysis
- 16.3.9.4. Strategic Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook